XML 23 R1.htm IDEA: XBRL DOCUMENT v3.24.0.1
Cover - USD ($)
$ in Billions
 12 Months Ended
Dec. 31, 2023
Feb. 26, 2024
Jun. 30, 2023
Cover [Abstract]      
Document Type 10-K    
Document Annual Report true    
Document Period End Date Dec. 31, 2023    
Current Fiscal Year End Date --12-31    
Document Transition Report false    
Entity File Number 001-33093    
Entity Registrant Name LIGAND PHARMACEUTICALS INC    
Entity Incorporation, State or Country Code DE    
Entity Tax Identification Number 77-0160744    
Entity Address, Address Line One 555 Heritage Drive, Suite 200    
Entity Address, City or Town Jupiter    
Entity Address, State or Province FL    
Entity Address, Postal Zip Code 33458    
City Area Code 858    
Local Phone Number 550-7500    
Title of 12(b) Security Common Stock, par value $.001 per share    
Trading Symbol LGND    
Security Exchange Name NASDAQ    
Entity Well-Known Seasoned Issuer Yes    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Large Accelerated Filer    
Entity Small Business false    
Entity Emerging Growth Company false    
ICFR Auditor Attestation Flag true    
Document Financial Statement Error Correction [Flag] false    
Entity Shell Company false    
Entity Public Float     $ 0.9
Entity Common Stock, Shares Outstanding   17,705,287  
Documents Incorporated by Reference
Portions of the Proxy Statement for the Registrant’s 2024 Annual Meeting of Stockholders to be filed with the Commission within 120 days of December 31, 2023 are incorporated by reference in Part III of this Annual Report on Form 10-K. With the exception of those portions that are specifically incorporated by reference in this Annual Report on Form 10-K, such Proxy Statement shall not be deemed filed as part of this Report or incorporated by reference herein.
    
Amendment Flag false    
Document Fiscal Year Focus 2023    
Document Fiscal Period Focus FY    
Entity Central Index Key 0000886163